{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361137045609202176.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/sj.ki.5001872"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0085253815522047?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0085253815522047?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"16985512"}}],"dc:title":[{"@value":"Local delivery of angiotensin receptor blocker into the kidney ameliorates progression of experimental glomerulonephritis"}],"description":[{"notation":[{"@value":"Intrarenally synthesized angiotensin II (Ang II) may be involved in the progression of glomerulonephritis, leading to irreversible glomerulosclerosis. There is increasing evidence that systemic angiotensin receptor blocker (ARB) treatment has beneficial effect on the prognosis of progressive glomerulonephritis and diabetic nephropathy. However, the cellular and molecular mechanisms behind this therapeutic effect of ARB remain unclear. In this study, we used a novel strategy of local ARB delivery via type-1 collagen sponge, to treat progressive glomerulonephritis that would result in irreversible glomerulosclerosis in our previously established rat model. At days 9 and 14 after disease induction, mild proteinuria, 20.7+/-4.7 and 10+/-1.3 mg/day, was found. Local ARB treatment reduced proteinuria significantly to 3.19+/-3.2 and 5.25+/-0.95 mg/day (P0.01), respectively. Scoring of glomerular matrix expansion and sclerotic index revealed that local ARB treatment significantly ameliorated glomerular pathology. Ang II type 1 receptor mRNA expression was remarkably enhanced in the Ang II group and ARB treatment reversed this effect at 14 days. Local delivery of ARB significantly improved glomerular blood flow levels, compared to the untreated disease control group, from 710+/-18.25 to 859.44+/-22.86 microm/s, respectively. Local delivery of ARB into the kidney affected local RAS and thus improved the renal injury and function in the potentially progressive glomerulosclerosis of rat model."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380004054007371014","@type":"Researcher","foaf:name":[{"@value":"J. Mahmood"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045609202178","@type":"Researcher","foaf:name":[{"@value":"F. Khan"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045609202180","@type":"Researcher","foaf:name":[{"@value":"S. Okada"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045609202176","@type":"Researcher","foaf:name":[{"@value":"N. Kumagai"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045609202177","@type":"Researcher","foaf:name":[{"@value":"T. Morioka"}]},{"@id":"https://cir.nii.ac.jp/crid/1381137045609202179","@type":"Researcher","foaf:name":[{"@value":"T. Oite"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"00852538"},{"@type":"PISSN","@value":"http://id.crossref.org/issn/00852538"}],"prism:publicationName":[{"@value":"Kidney International"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2006-11","prism:volume":"70","prism:number":"9","prism:startingPage":"1591","prism:endingPage":"1598"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","http://www.elsevier.com/open-access/userlicense/1.0/"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0085253815522047?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0085253815522047?httpAccept=text/plain"}],"createdAt":"2006-09-20","modifiedAt":"2024-02-06","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Kidney%20Glomerulus","dc:title":"Kidney Glomerulus"},{"@id":"https://cir.nii.ac.jp/all?q=Tetrazoles","dc:title":"Tetrazoles"},{"@id":"https://cir.nii.ac.jp/all?q=Nephrectomy","dc:title":"Nephrectomy"},{"@id":"https://cir.nii.ac.jp/all?q=Receptor,%20Angiotensin,%20Type%201","dc:title":"Receptor, Angiotensin, Type 1"},{"@id":"https://cir.nii.ac.jp/all?q=Renin-Angiotensin%20System","dc:title":"Renin-Angiotensin System"},{"@id":"https://cir.nii.ac.jp/all?q=Glomerulonephritis","dc:title":"Glomerulonephritis"},{"@id":"https://cir.nii.ac.jp/all?q=Isoantibodies","dc:title":"Isoantibodies"},{"@id":"https://cir.nii.ac.jp/all?q=Animals","dc:title":"Animals"},{"@id":"https://cir.nii.ac.jp/all?q=Vasoconstrictor%20Agents","dc:title":"Vasoconstrictor Agents"},{"@id":"https://cir.nii.ac.jp/all?q=RNA,%20Messenger","dc:title":"RNA, Messenger"},{"@id":"https://cir.nii.ac.jp/all?q=angiotensin%20receptor%20blocker","dc:title":"angiotensin receptor blocker"},{"@id":"https://cir.nii.ac.jp/all?q=Rats,%20Wistar","dc:title":"Rats, Wistar"},{"@id":"https://cir.nii.ac.jp/all?q=Drug%20Implants","dc:title":"Drug Implants"},{"@id":"https://cir.nii.ac.jp/all?q=Angiotensin%20II","dc:title":"Angiotensin II"},{"@id":"https://cir.nii.ac.jp/all?q=Microcirculation","dc:title":"Microcirculation"},{"@id":"https://cir.nii.ac.jp/all?q=Valine","dc:title":"Valine"},{"@id":"https://cir.nii.ac.jp/all?q=Rats","dc:title":"Rats"},{"@id":"https://cir.nii.ac.jp/all?q=glomerular%20hemodynamics","dc:title":"glomerular hemodynamics"},{"@id":"https://cir.nii.ac.jp/all?q=renin","dc:title":"renin"},{"@id":"https://cir.nii.ac.jp/all?q=Gene%20Expression%20Regulation","dc:title":"Gene Expression Regulation"},{"@id":"https://cir.nii.ac.jp/all?q=Nephrology","dc:title":"Nephrology"},{"@id":"https://cir.nii.ac.jp/all?q=Disease%20Progression","dc:title":"Disease Progression"},{"@id":"https://cir.nii.ac.jp/all?q=Valsartan","dc:title":"Valsartan"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Angiotensin%20II%20Type%201%20Receptor%20Blockers","dc:title":"Angiotensin II Type 1 Receptor Blockers"},{"@id":"https://cir.nii.ac.jp/all?q=glomerulosclerosis","dc:title":"glomerulosclerosis"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1390001204146310400","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Exploring the mechanisms of renoprotection against progressive glomerulosclerosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001204338495616","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The mechanisms of progressive glomerulosclerosis"},{"@language":"ja","@value":"糸球体硬化に至る腎炎進行機構―微小循環動態解析からの解明―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206430471424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Association between the Intrarenal Renin-Angiotensin System and Renal Injury in Chronic Kidney Disease of Dogs and Cats"}]},{"@id":"https://cir.nii.ac.jp/crid/2050870367073817216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The effect of renal administration of a selective cyclooxygenase-2 inhibitor or stable prostaglandin I2 analog on the progression of sclerotic glomerulonephritis in rats"}]},{"@id":"https://cir.nii.ac.jp/crid/2051151842050541312","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Local delivery of a direct renin inhibitor into the kidney ameliorates progression of experimental glomerulonephritis"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/sj.ki.5001872"},{"@type":"OPENAIRE","@value":"doi_dedup___::17c35a31013fe7646b70ec71733ec3f8"},{"@type":"CROSSREF","@value":"10.1007/s10157-012-0601-y_references_DOI_Y25b39zh2BV11Jj088taCirjyLf"},{"@type":"CROSSREF","@value":"10.1292/jvms.12-0314_references_DOI_Y25b39zh2BV11Jj088taCirjyLf"},{"@type":"CROSSREF","@value":"10.3165/jjpn.26.232_references_DOI_Y25b39zh2BV11Jj088taCirjyLf"},{"@type":"CROSSREF","@value":"10.1007/s10157-011-0558-2_references_DOI_Y25b39zh2BV11Jj088taCirjyLf"},{"@type":"CROSSREF","@value":"10.2183/pjab.87.81_references_DOI_Y25b39zh2BV11Jj088taCirjyLf"}]}